Last reviewed · How we verify
NCT02491541
A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years
Phase 3 trial testing Changchun Werersai in Rabies in 1,200 participants. Completed in 1 December 2013.
1 December 2012
Quick facts
| Lead sponsor | Jiangsu Province Centers for Disease Control and Prevention |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 1,200 |
| Start date | 1 August 2012 |
| Primary completion | 1 December 2012 |
| Estimated completion | 1 December 2013 |
| Sites | 1 location across China |
Drugs / interventions tested
- Changchun Werersai — full drug profile →
- Jilin Maifeng — full drug profile →
Conditions studied
- Rabies — all drugs for Rabies →
Sponsor
Jiangsu Province Centers for Disease Control and Prevention — full company profile →
Who can join
Adults 10 to 60, any sex, with Rabies. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Positive seroconversion rate of serum rabies virus neutralizing antibody 42 days after full vaccination
Time frame: 42 days after full vaccination
Sponsor's own description
The purpose of this single-centre, randomized, double-blind, parallel control, phase 3 study is to evaluate the safety and immunogenicity of a rabies vaccine (Vero Cell) for human use in healthy Chinese subjects aged 10-60 years, according to the Essen methods (1-1-1-1-1) vaccination.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02491541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rabies
Currently open trials in the same condition.
- NCT07275645 — A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years · Phase 3 · active not recruiting
- NCT07021703 — A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried · Phase 1 · recruiting
- NCT06998004 — A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and · Phase 1 · recruiting
Other Jiangsu Province Centers for Disease Control and Prevention trials
Trials by the same sponsor.
- NCT07530679 — Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vacc · NA · not yet recruiting
- NCT07232745 — Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine · Phase 4 · active not recruiting
- NCT06609811 — The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuat · Phase 4 · completed
- NCT07035054 — Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine · Phase 2 · completed
- NCT07025876 — PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02491541 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Province Centers for Disease Control and Prevention
- Last refreshed: 8 July 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02491541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing